Candriam SCA’s Altimmune ALT Stock Holding History

Candriam SCA’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200,000	Closed	-$3.29M	–	878
2022 Q4	$3.29M	Hold	200,000	–	–	0.02%	472
2022 Q3	$2.55M	Buy	+200,000	New	+$2.95M	0.02%	531

Other funds holding ALT

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Candriam SCA's ALT Position: Q1 2023 in Review

Candriam SCA sold out of Altimmune (ALT) in Q1 2023, closing a stake of 200,000 shares — an estimated $3.29M sold.

Candriam SCA first reported a position in ALT in Q3 2022 and held it in 2 quarters. The position peaked at $3.29M in Q4 2022. 132 funds tracked by Wall St. Rank hold ALT as of Q1 2023.

Candriam SCA reported no remaining Altimmune position as of Q1 2023 after selling out during the quarter.
Candriam SCA sold 200,000 Altimmune shares in Q1 2023, an estimated $3.29M.
Candriam SCA first reported a position in Altimmune in Q3 2022 and held it in 2 quarters.
Candriam SCA's Altimmune position peaked at $3.29M in Q4 2022.
132 funds tracked by Wall St. Rank held Altimmune as of Q1 2023.

Based on Candriam SCA's 13F filing for Q1 2023, filed 12 May 2023.